Back to News
Market Impact: 0.3
IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
IDEAYA Biosciences reported updated Phase 1 results for IDE849, an investigational DLL3-targeted antibody-drug conjugate, showing antitumor activity in relapsed small cell lung cancer and other neuroendocrine carcinomas. The article provides no response rates, safety details, or other numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IDYA0.65
More News
- IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs